PDF factsheet
      Z

fibrinolysis in acute coronary syndrome for all type of patients, clinical trials results

anistreplase versus placebo
UNASEM, 1992
anistreplase IV 30 UI over 5 minutes
versus
placebo
Patients without a previous myocardial infarction, with a typical history of unstable angina and ECG abnormalities indicative of ischemia double blind
Follow-up duration: hospital stay, 1y
Europe
intracoronary urokinase versus placebo
TAUSA, 1994
intracoronary urokinase 250000 UI or 500000 UI
versus
placebo
ischemic rest pain with or without a recent (< 1 month) infarction double blind
Follow-up duration: hospital stay
USA
t-PA versus placebo
Nicklas, 1989
rt-PA, 150 mg/8 h
versus
placebo
patients with rest angina, angiographically documented coronary artery disease and pacing-induced ischemiaDouble blind
USA
Gold, 1987
intravenous recombinant human tissue-type plasminogen activator (rt-PA).
versus
placebo
chest pain at rest with transient ST segment deviation of at least 1 mm
Williams, 1990
tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour or (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
versus
placebo
rest angina and angiographic evidence of coronary stenosis double blind
USA
Freeman, 1992
tissue-type plasminogen activator (t-PA) (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours)
versus
placebo
patients with unstable angina double blind
Follow-up duration: in hospital
USA
van der Brand, 1991
alteplase 100 mg in 3 h
versus
placebo
patients with angina at rest, despite bedrest and medical treatment double blind
Follow-up duration: hospital stay
The Netherlands
charbonnier, 1992
rt-PA 100 mg/90 minutes (10 mg bolus + 90 mg/90 minutes
versus
placebo
unstable angina pectoris double blind
Ardissino, 1990
recombinant tissue-type plasminogen activator (rt-PA) followed by heparin
versus
heparin alone
unstable angina refractory to conventional medical treatmentdouble blind
Follow-up duration: in hospital
Italy
TIMI 3B, 1995
tissue-type plasminogen activator (t-PA)
versus
placebo
patients with unstable angina and non-Q wave myocardial infarctionDouble blind
Follow-up duration: 1 year
Topol, 1988
intravenous tissue plasminogen activator (t-PA)
versus
placebo
patients with angina at rest and provocable ischemia (pacing induced) open
Follow-up duration: hospital stay
USA
TIMI 3A, 1993
90-minute front-loaded infusion of t-PA (0.8 mg/kg i.v.; maximum, 80 mg)
versus
placebo
patients with unstable angina or non-Q wave myocardial infarctiondouble blind
Follow-up duration: hospital stay
USA, canada

  Options


in first

in second

  Filter